文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Mezigdomide and Multiple Myeloma.

作者信息

Shortt Jake

机构信息

From the Department of Medicine, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing, and Health Sciences, Monash University, and Monash Haematology, Monash Health - both in Clayton, VIC, Australia.

出版信息

N Engl J Med. 2023 Sep 14;389(11):1046-1050. doi: 10.1056/NEJMe2307370. Epub 2023 Aug 30.

DOI:10.1056/NEJMe2307370
PMID:37646699
Abstract
摘要

相似文献

[1]
Mezigdomide and Multiple Myeloma.

N Engl J Med. 2023-9-14

[2]
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.

N Engl J Med. 2023-9-14

[3]
Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide.

Expert Rev Hematol. 2024-8

[4]
Mezigdomide Data Show CELMoD Potential.

Cancer Discov. 2023-11-1

[5]
New Therapies on the Horizon for Relapsed Refractory Multiple Myeloma.

Hematol Oncol Clin North Am. 2024-4

[6]
Novel strategies in the treatment of relapsed/refractory multiple myeloma. From the Multiple Myeloma Research Foundation.

Oncology (Williston Park). 2003-8

[7]
[Multiple Myeloma: from Diagnosis to the Up-to-date Treatment. Topics: VIII. Novel Drugs for Multiple Myeloma].

Nihon Naika Gakkai Zasshi. 2016-7

[8]
Introduction to therapies in multiple myeloma.

Semin Hematol. 2001-7

[9]
Multiple Myeloma: Multiplying Therapies.

Clin Cancer Res. 2016-11-15

[10]
Integration of novel agents into treatment of myeloma.

Clin Lymphoma Myeloma. 2007-8

引用本文的文献

[1]
The Role of CELMoD Agents in Multiple Myeloma.

Onco Targets Ther. 2025-8-27

[2]
Targeting degradation of IKZF1 and IKZF3 through modulation of the E3 ligase substrates in the context of cellular therapies for multiple myeloma.

Biomark Res. 2025-8-15

[3]
METTL5 regulates SEPHS2-mediated selenoprotein synthesis to promote multiple myeloma survival and progression.

Cell Death Dis. 2025-8-2

[4]
The Genetic and Molecular Drivers of Multiple Myeloma: Current Insights, Clinical Implications, and the Path Forward.

Pharmgenomics Pers Med. 2024-12-21

[5]
Mezigdomide-A Novel Cereblon E3 Ligase Modulator under Investigation in Relapsed/Refractory Multiple Myeloma.

Cancers (Basel). 2024-3-15

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索